Risk & Economy » Regulation » Financing falls a third

However, the decline was steeper in the US, where investment fell 65%, transaction volume fell 53% and pre-money valuations declined from EUR28.5m to EUR19m during the same period. Biopharmaceuticals saw a 13% increase in funding over the year, to EUR1.7bn euros in 160 deals.